Attached files
| file | filename |
|---|---|
| 8-K - BOVIE 8K RE NEW GENERAL COUNSEL - Apyx Medical Corp | bovie8knewgeneralcounsel.htm |
| EX-10.1 - LEONARD KEEN EMPLOYMENT AGREEMENT - Apyx Medical Corp | lkemploymentagt.htm |
BOVIE
MEDICAL CORPORATION ANNOUNCES
LEONARD
KEEN AS GENERAL COUNSEL
Melville,
New York, March 8, 2010 - Bovie Medical Corporation (the “Company”) (NYSE-AMEX
Symbol: BVX), a manufacturer and marketer of electrosurgical products, today
announced that it has employed Mr. Leonard Keen, Esq. as Vice President and
General Counsel, effective March 2, 2010. Mr. Keen is responsible for
managing the Company’s legal and strategic affairs, and working as a member of
the executive management team to strengthen operations for growth and
competitiveness.
“We are
pleased that Mr. Keen has joined Bovie at this time. He is
multi-skilled and will be involved in areas of the Company’s business
development requiring his legal and technical advice,” stated Andrew Makrides,
President and Chief Executive Officer of Bovie Medical.
Prior to
joining the Company, Mr. Keen has worked as an attorney, business executive,
entrepreneur and technologist. He served as a partner with Kaplan, Ward
& Patel, an associate with Allen Dyer Doppelt Milbrath & Gilchrist and a
solo practitioner where he specialized in intellectual property and business
law. He also served as Vice President of Legal and Strategic Affairs at
Kinetics, Inc. (a NCR Subsidiary) and as Chief Information Officer at Payroll
Transfers, Inc.
Mr. Keen
received a Bachelor of Science degree in Chemistry/Mathematics from the
University of Miami and a Juris Doctor, with honors, from the University of
Florida Levin College of Law. In addition to being a U.S. registered
patent attorney and member of the Florida Bar, Mr. Keen has extensive experience
in the technical, business and executive management fields.
An
employment agreement with Mr. Keen was entered into on March 2, 2010, and as
part thereof, he was awarded a restricted non-qualified stock option for an
aggregate of 100,000 shares of common stock, exercisable at the closing price on
that date. The option has a ten year term and vests over seven years,
or at the rate of 14.29 percent per annum. This press release is
issued in accordance with the exemption afforded under Section 711(a) of the
NYSE AMEX Company Guide which exempts certain stock option grants made as an
inducement to employment from the stockholder approval requirement.
For
further information about the Company’s current and new products, please refer
to the Investor Relations section of Bovie’s website www.boviemedical.com.
Certain
matters discussed in this news release and oral statements made from time to
time by representatives of the Company may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based upon
reasonable assumptions, it can give no assurance that its expectations will be
achieved.
Forward-looking
information is subject to certain risks, trends and uncertainties that could
cause actual results to differ materially from those projected. Many
of these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements contained in
this news release can be found in the Company’s filings with the Securities and
Exchange Commission. For forward-looking statements in this new
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995. The Company assumes no obligation to update or
supplement any forward-looking statements whether as a result of new
information, future events or otherwise.
Investor
Contact:
Buttonwood
Advisory Group, Inc.
John
Aneralla
1-800-940-9087